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Abstract Themain objective of this study was to showdose-dependentequivalence in the systemic activityof bude-
sonide 800 mgday71and1600 mgday71delivered fromeither Easyhaler1orTurbuhaler1 in healthymale subjects.
This single-centre study was carried out according to a randomized, double-blind, double-dummy, ¢ve-way cross-
overdesignover a 9-weekperiod.Allsubjectsreceived1weekoftreatmentwiththe following, inrandomizedorder,with
awashoutweekbetweeneachtreatment: budesonide Easyhaler1 800 mgday71plusplaceboTurbuhaler1; budesonide
Easyhaler11600 mgday71plus placeboTurbuhaler1; placebo Easyhaler1plus Pulmicort1 Turbuhaler1 800 mgday71;
placebo Easyhaler1 plus Pulmicort1 Turbuhaler11600 mgday71; placebo Easyhaler1 plus placeboTurbuhaler1.The
¢nal inhalation of studydrugwasperformed atthe studycentre, where blood andurine sampleswere collected.
Fifteen subjects were recruited and all completed the study.Mean serum cortisol AUC0^20 values (the primary out-
comevariable) were comparable foreachdevice atthetwodoselevels, andmetthede¢nedcriteria forequivalence (90%
CI 0?8^1?25 forbetween-treatmentdi¡erence).Budesonide 800 mgday71causedminimal suppression of serumcortisol
AUC0-20 values. Budesonide 1600 mgday
71 statistically signi¢cantly suppressed serum cortisol AUC0^20 values com-
pared with placebo.Meanmorning serum cortisol values were within the reference range in all treatment groups. At a
budesonide dose of 800 mgday71 mean urine cortisol/creatinine ratio was statistically signi¢cantly higher with Easy-
haler1 thanwithTurbuhaler1, but there was no signi¢cant di¡erence between the devices at the1600 mgday71dose.
Serum budesonide concentrations were equivalent for each device at both dose levels. Adverse drug reactions were
infrequent andmild innature and therewereno clinically signi¢cantchanges in laboratory safety variables.
In conclusion, in healthymale volunteers, budesonide 800 mgday71 and1600 mgday71 inhaled from Easyhaler1 had
comparable systemic e¡ects to the same doses inhaledviaTurbuhaler1.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1157, available online at http://www.idealibrary.comon
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Budesonide is a potent glucocorticosteroid, with well-
documented e⁄cacy in the treatment of asthmatic pa-
tients (1). When inhaled, the systemic bioavailability of
budesonide results primarily from absorption across the
lung vascular bed, while any swallowed drug undergoes
extensive ¢rst-passmetabolism in the liver (2,3). Pharma-
cokinetic studies of budesonide have demonstrated that
about 30% of the inhaled dose is bioavailable (4).
Dose-related suppressive e¡ects onHPA axis function
have been observed with budesonide (5,6).The systemic
markers most commonly used to monitor these e¡ects
in humans are serum and/or urinary cortisol (7). These
measures can be made more sensitive by determiningReceived 6 March 2001and accepted in revised form11June 2001.
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um cortisol measurements, and by correcting urinary
cortisol excretion for creatinine [urinary cortisol/creati-
nine (UCC) ratio].
A key element in determining the systemic bioavail-
ability of an inhaled corticosteroid is the delivery device
(8). Hence, it is important to document the systemic ef-
fects of an agent in relation to theparticulardevices from
which it will be inhaled.One of themostwidely used de-
vices for the delivery of corticosteroids in most of Eur-
ope is the pressurizedmetered-dose inhaler (pMDI) (9).
However, these devices are associated with a number of
problems, including under-dosing due to poor hand^
breath coordination (10) and airway irritation from the
lubricants or propellants used (11).
In order to overcome the drawbacks of pMDIs,
breath-actuated multi-dose dry powder inhalers were
developed, of which Turbuhaler1 was one of the ¢rst,
and is well documented for the delivery of budesonide
864 RESPIRATORYMEDICINE(12^15). Easyhaler1 is a new-generation dry powder
inhaler currently documented and registered for
the delivery of salbutamol (16) and beclometasone
dipropionate (17).
The main purpose of the present study was to com-
pare the systemic activity of budesonide, at clinically re-
commended dose levels (800mgday71 and
1600mgday71), delivered from Easyhaler1 andTurbuha-
ler1 in healthymale subjects.Threemeasureswereused
to assess the potential e¡ect of budesonide on HPA axis
function: morning (08?00h) serum cortisol, area under
the curve (AUC) for repeated serum cortisol measure-
ments and urinary cortisol/creatinine (UCC) ratio. Ser-
um budesonide concentrations were also determined.
MATERIALSANDMETHODS
Subjects
Healthy male volunteers, aged 18^40 years, were re-
cruited into the study. In order to be included in the
study, theyhad to benon-smokers (for at least 6months)
with a body mass index of 19^26kgm72, and to have
normal health as determinedbypreviousmedical history
and both physical and laboratory examinations per-
formedwithin 30 days before study entry.
Study design
The study was carried out at a single centre (the Phar-
macokinetic Unit of the Department of Medical Product
Maintenance and Pharmacokinetics, Orion Pharma,
Kuopio, Finland) according to a randomized, placebo-
controlled, double-blind, double-dummy, ¢ve-way
cross-over design. Both of the dry powder inhalers
used in the study, budesonide Easyhaler1 (Orion
Pharma, Espoo, Finland) and Pulmicort1 Turbuhaler1
(AstraZeneca, Lund, Sweden), delivered budesonide at a
dose of 400mgper inhalation. After careful instruction in
the technique for each device, all subjects received the
following treatment regimens for 1 week each, in
randomized order, with a 1-week washout period
between each treatment:
. budesonide Easyhaler1, 400mgdose71, one inhalation
twice daily (800mgday71) plus placebo Turbuhaler1
one inhalation twice daily;
. budesonide Easyhaler1, 400mgdose71, two
inhalations twice daily (1600mgday71) plus placebo
Turbuhaler1 two inhalations twice daily;
. placebo Easyhaler1, one inhalation twice daily plus
Pulmicort1 Turbuhaler1 400mgdose71, one
inhalation twice daily (800mgday71);
. placebo Easyhaler1, two inhalations twice daily plus
Pulmicort1 Turbuhaler1 400mgdose71, two
inhalations twice daily (1600mgday71);. placebo Easyhaler1, one inhalation twice daily plus
placeboTurbuhaler1, one inhalation twice daily.
Thus, the total study period lasted for 9 weeks, com-
prising ¢ve treatment weeks with 4 washout weeks in
between each treatment week. Subjects were in-
structed to perform inhalation(s) at 08?00h and 20?00h
from the devices. After each inhalation, subjectswere in-
structed to hold their breath for 5^10 sec before exhal-
ing, and to rinse their mouth with water and spit it out
after each inhalation. Before the study days, all subjects
learned to inhale with an optimal inspiratory £ow rate
using a peak inspiratory £ow (PIF) meter, designed for
Easyhaler1.
Of the14 inhalations in each treatment week,13 were
performed at home and the last was performed at
20?00h at the Pharmacokinetic Unit under the supervi-
sion of the study personnel. Blood samples (5ml) were
drawn in the week before starting treatment (baseline)
and on the last day of each treatment week at multiple
time points: before inhaling the last dose (time 0), and
every 2h up to 20h after it. For 24h prior to each study
visit, subjects were instructed to avoid strenuous exer-
cise, eat normal meals and to avoid cold air (7208C for
several h), alcohol and sauna.They were also instructed
to fast from16?00h. onwards on the dayof the study visit
and to stay in bed from 00?00h until 07?00h the follow-
ingmorning.
The blood samples were allowed to clot (approxi-
mately 30min) and the serum was separated by
centrifugation and stored at 7208C until analysed.
Serum cortisol analysis was performed using a
radioimmunoassay method at Oy Medix Ab, Helsinki,
Finland. The AUC0^20 was calculated using BIOPAK
software (Statistical Consultants, Inc., Lexington,
Kentucky, U.S.A.) according to the trapezoidal rule.
Mean single morning serum cortisol concentrations at
08?00h were also calculated. For each blood sample
(0720h), serum budesonide concentrations were
also determined using a combination of high perfor-
mance liquid chromatography (HPLC) andmass spectro-
metry at the Department of Bioanalytics and
Pharmacokinetics of Orion Pharma, Espoo, Finland.
The pharmacokinetic parameters AUC0^20, Cmax and
tmax for budesonide were calculated using BIOPAK
software.
Urine was collected at the study site in one12-h frac-
tion. Subjects were instructed to empty their bladder
immediately before the last inhalation(s) of study drugs.
Thereafter, urinewas collected and stored in a refrigera-
tor at +48Cuntil completion of the12-h period. Samples
(5ml and10ml) were then transferred to test tubes and
stored at 7208C until analysed. Urine cortisol values
were analysedwithHPLC (18), and creatinine determina-
tionswereperformedby spectrophotometry atHelsinki
University Hospital.
TABLE 1. Demographic andbaseline subjectinformation
(n=15)
Parameter Mean (SD)
Age (years) 25 (2)
Height (cm) 177 (4)
Weight (kg) 73 (6)
BMI (kgm72) 23 (1)
Heart rate (beatsmin71) 61 (13)
Bloodpressure (mmHg)
Systolic 130 (8)
Diastolic 80 (7)
FIG. 1. Mean (SD) serum cortisol AUC0^20 values (nmol?hl
71).
(&) Easyhaler1 and (&) Turbuhaler1. **P50?01 vs. placebo
and 800 mg Easyhaler1.
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boratory parameters before and after study. In addition,
subjects recorded all adverse events in their treatment
diaries. At each study visit, the investigators also per-
formed oropharyngeal swabs to determine the presence
of Candida albicans; use of any anti-mycotic medication
was recorded in the diaries.
Compliance with study treatment was assessed by
subjects’daily diary records and by the return of all used
Easyhalers1 and Turbuhalers1.
The study protocol and amendments were reviewed
and approved by the Ethics Committee of Orion Phar-
ma, Finland. All subjects were required to give written
informed consent and the study was conducted accord-
ing to the principles of the current revision of the De-
claration of Helsinki (19).
Outcome variables
The primary outcome variable was serum cortisol
AUC0^20. For each dose/device comparison, the follow-
ing variables were also analysed: morning (08?00h) ser-
um cortisol, serum budesonide values (AUC0^20, Cmax
and tmax) and UCC ratio. Finally, laboratory values and
adverse events (whether related to study drug or not)
were recorded in each case.
Statistical analysis
The primary hypothesis of the study was that, at equal
daily doses, Budesonide Easyhaler1 and Pulmicort1Tur-
buhaler1 would have an equivalent e¡ect on serum cor-
tisol AUC0^20. Equivalence was de¢ned as 90% CI
0?871?25 for test/reference ratio at each dose level.
Treatment di¡erences for other outcome variables (as
described above) were analyzed in a similar way.
Mixed analysis of variance (ANOVA) models were
used in the analysis of serum cortisol AUC0^20, morning
serum cortisol, UCC ratio and serum budesonide con-
centrations. For serum budesonide concentrations, 95%
CI was estimated; for all other variables, 90% CI was es-
timated.
It was estimated that the 0?9 power needed to assess
equivalence using 0?871?25 criterion for test/reference
ratios would be attained with12 subjects. In order to al-
low discontinuations or protocol violations, 15 subjects
were recruited into the study.
RESULTS
Subjects
Demographic and baseline characteristics of the15 sub-
jects recruited into the study are shown in Table 1. All
subjects completed the study and were evaluable for
safety.Compliance
According to the daily diary records, 100% of the pre-
scribed dose of study drug was used in each treatment
course.
Safety
Serum cortisol AUC0^20
Mean serumcortisol AUC0^20 valueswere similar in sub-
jects using budesonide Easyhaler1 800mgday71and Pul-
micort1 Turbuhaler1 800mgday71 (90% CI for ratio
0?89^1?04), and in those using budesonide Easyhaler1
1600mgday71 and Pulmicort1 Turbuhaler1
1600mgday71 (90% CI for ratio 0?87^1?03) (Fig. 1, Table
2).Thus, 90% CIs at each dose level were within the pre-
de¢ned criteria for equivalence. There was no statisti-
cally signi¢cant di¡erence between budesonide
Easyhaler1 800mgday71andplacebo.Mean serumcorti-
sol AUC0^20 values were statistically signi¢cantly lower
for budesonide Easyhaler11600mgday71comparedwith
placebo (P=0?008) and compared with budesonide Easy-
haler1 800mgday71 (P=0?005).
FIG. 2. Individualmorning (08?00 h) serumcortisolconcentrations andmean (indicatedbybar).Thelineindicates thelowerreference
limit (190 nmoll71).
TABLE 2. Mean (SD) values for serumcortisol AUC0^20 (nmol?hl
71), morning (08?00 h) serumcortisol (nmoll71) and
UCCratio nmolmmol71 (n=15 in each case)
Budesonide 800 mgday71from Budesonide1600 mgday71from
Baseline Placebo Easyhaler1 Turbuhaler1 Easyhaler1 Turbuhaler1
Serumcortisol
AUC0^20
4408?6 (621?6) 4027?6 (518?1) 3741?7 (619?2) 3837?9 (659?7) 3272?9 (397?2)*,
{ 3315?5 (608?3)
Morning serum
cortisol
460?0 (64?7) 407?3 (117?0) 358?0 (120?8) 358?7 (145?0) 287?2 (158?5) 291?5 (132?3)
UCCratio 2?01 (1?27) 1?56 (0?99) 1?53 (0?99){ 1?05 (0?46) 1?30 (0?60) 1?11 (0?42)
*P=0?008 vs. placebo.
{P=0?005 vs.Easyhaler1 800 mgday71.
{P=0?046 vs.Turbuhaler1 800 mgday71.
866 RESPIRATORYMEDICINEMorning serum cortisol
Mean morning (08?00h) serum cortisol values were
above the lower limit of the normal reference range
(190nmol l71) in all treatment groups, and there were
no statistically signi¢cant di¡erences between any of the
groups (Fig. 2, Table 2). Analysis of individual values
showed that two subjects in the Turbuhaler1
800mgday71 group but none in the Easyhaler1
800mgday71 group had values 5190nmol l71 (Fig. 2).
At the1600mgday71dose of budesonide, ¢ve subjects in
the Easyhaler1 group and three subjects in the
Turbuhaler1 grouphadvaluesbelow the lowerreference
limit.
UCC ratio
ThemeanUCCratiowas statistically signi¢cantly higher
for Easyhaler1 800mgday71 than Turbuhaler1800mgday71 (P=0?046, ratio 1?38, 90% CI 1?06^1?80).
However, there was no signi¢cant di¡erence between
the devices at the 1600mgday71 dose, nor between
either of the Easyhaler1 groups and placebo (Table 2).
Serumbudesonide concentrations
In terms of serum budesonide concentrations (AUC0^20
and Cmax), there were no statistically signi¢cant di¡er-
ences between Easyhaler1 and Turbuhaler1 at
800mgday71, nor at 1600mgday71 (Table 3). However,
as expected, there were signi¢cant di¡erences in serum
budesonide values between the 800mgday71 and
1600mgday71dose levels for each device. Serumbudeso-
nide concentration/time curves are shown in Fig. 3. Lack
of samples between 0 and 2h, and 2 and 4h has an e¡ect
on the concentration/time curves, showing a Cmax at 2h
(tmax) after the last inhalation of the study drugs.
TABLE 3. Mean (SD) values for serumbudesonide AUC0^20 (pg?hml
71) and Cmax (pgml
71) (n=15 in each case)
Budesonide 800 mgday71from Budesonide1600 mgday71from
Easyhaler1 Turbuhaler1 Easyhaler1 Turbuhaler1
Serumbudesonide AUC0-20 1461?7 (903?8) 1252?3 (633?2) 2904?3 (1379?4)* 2992?3 (795?2)
{
Serumbudesonide Cmax 289?3 (140?3) 284?9 (91?6) 545?2 (189?6)
{ 587?5 (114?1)}
*P=0?0002 vs.Turbuhaler1 800 mgday71.
{P=0?0001vs.Easyhaler1 800 mgday71.
{P=0?0001vs.Turbuhaler1 800 mgday71.
}P50?0001vs.Easyhaler1 800 mgday71.
FIG. 3. Serum budesonide concentration/time curves.
Means+SD. (&) Easyhaler1 800 mg, (*) Turbuhaler1 800 mg,
(&) Easyhaler11600 mgand (*) Turbuhaler11600 mg.
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The overall incidence of adverse events during the study
was low. Sixteen ADRs were reported. All were mild in
nature and were considered only possibly related to
study drug.Therewere no cases of oropharyngeal candi-
diasis and no serious adverse events occurred during the
study.
DISCUSSION
The purpose of this study was to investigate the sys-
temic activity of inhaled budesonide at a daily dose of
800mg and 1600mg from Easyhaler1 or Turbuhaler1
measured as the e¡ect on HPA-axis function. Healthy
male volunteers were selected for this study because
they have shown to bemore sensitive than asthmatic pa-
tients to the systemic e¡ects of inhaled steroids (6).
A study period of1week was established to reach the
maximum systemic e¡ect of budesonide. The washout
period of1weekwas used on thebasis of an earlier study
(20) as well as prior reports that a washout period of at
least 48h is necessary when assessing the systemice¡ects of di¡erent inhaled corticosteroids (21). In addi-
tion, the degree of adrenal suppression seen with re-
peated twice daily dosing re£ectsmore accurately what
may be expected in clinical practice (22). It has been re-
ported that even single dosingmaybe usedwith budeso-
nidewhen systemic e¡ects are determined (23). A cross-
over design was used so that the subjects could serve as
their own controls, which reducederror variance aswell
as the number of subjects needed for statistical analysis.
The two dose levels of budesonide to be tested were
chosen because 800mgday71 is an average dose for
maintenance treatment in asthmatic patients, and
1600mgday71 is the maximum recommended daily dose
in asthma. A placeboweek was included in the study be-
cause it has previously been reported that stress factors
associated with having blood drawn can increase serum
cortisol values.
The results of this study showed that budesonide at a
dailydose of 800mgday71fromboth Easyhaler1 andTur-
buhaler1 caused no statistically signi¢cant decrease in
serum cortisol AUC0^20 values, the primary study vari-
able, compared with placebo. At a daily dose of budeso-
nide 1600mgday71, serum cortisol values were
suppressed to a comparable and statistically signi¢cant
extent compared with placebo for both inhalers. At the
1600mg daily dose of budesonide, the highest per cent
suppression compared with placebo was 19% for serum
cortisol AUC0^20.
The results of this study are consistent with those of
earlier studies with inhaled budesonide. Multiple dosing
for 7 days with budesonide fromTurbuhaler1 in healthy
male volunteers resulted in19% plasma cortisol suppres-
sion in AUC0^24 at a dose of 800mgday
71 and 47% sup-
pression at a dose of 1600mgday71 (24). In addition,
L˛nnebo et al. noticed thatmultiple dosing with budeso-
nide fromTurbuhaler1 at1600mgday71resulted in a 34%
suppression of plasma cortisol (measured as AUC0^20 )
(25).
It has been suggested that suppression of plasma or
serum cortisol AUCvalues only becomes clinically signif-
icant when it exceeds 50% (24,26). Even at the higher
dailydose of budesonideused in thepresent study, serum
868 RESPIRATORYMEDICINEcortisol AUC0^20 suppression was only 19% compared
with placebo. The systemic e¡ects of budesonide on
morning serum cortisol and UCC ratios were in accor-
dancewith the e¡ects on serum cortisol AUC0^20.
In this study, serum budesonide concentrations were
also well matched at each dose of budesonide for each
inhaler used. After inhalation, budesonide is absorbed
rapidly and peak concentration is achieved within 20
min (27).Therefore, in further studies, in order to iden-
tify peak budesonide values more precisely, it may be of
value to increase the frequency of blood sampling
between 0 and 4h after inhalation.
The overall incidence of adverse events in the study
was low, and all those considered possibly related to
study drug were mild in nature. There were no di¡er-
ences in the frequency of ADRs between the placebo
and active treatments at either dose level.
CONCLUSIONS
In conclusion, 800mgday71of budesonide via Easyhaler1
or Turbuhaler1 had no statistically signi¢cant e¡ect on
serum cortisol AUC0^20 compared with placebo. At a
dose of 1600mgday71 the decrease in serum cortisol
AUC0^20 was statistically signi¢cant and comparable
with both devices. Serum budesonide concentrations at
both budesonide dose levels were comparable for the
two devices.Therewere no di¡erences in the tolerability
of budesonidewith either Easyhaler1 orTurbuhaler1.
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